{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:47:38Z","timestamp":1774957658844,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.dld.2023.09.023","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T11:20:59Z","timestamp":1697282459000},"page":"551-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6958-927X","authenticated-orcid":false,"given":"Rosa","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Cespiati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Francione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Maffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4591-0124","authenticated-orcid":false,"given":"Elena","family":"Del Zanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Maffeis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Colecchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Passigato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ferrarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina Daniela","family":"Cusumanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Villani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Grancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Airaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Bignamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Serviddio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Dongiovanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Fargion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Ludovica","family":"Fracanzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.dld.2023.09.023_bib0001","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S1262-3636(08)74597-X","article-title":"Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis","volume":"34","author":"Serfaty","year":"2008","journal-title":"Diabetes Metab"},{"issue":"4","key":"10.1016\/j.dld.2023.09.023_bib0002","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2023.09.023_bib0003","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2014.03.013","article-title":"Procoagulant imbalance in patients with non-alcoholic fatty liver disease","volume":"61","author":"Tripodi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.09.023_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/liv.13739","article-title":"Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease","author":"Bertot","year":"2018","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.dld.2023.09.023_bib0005","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.metabol.2015.08.018","article-title":"Genetics of nonalcoholic fatty liver disease","volume":"65","author":"Dongiovanni","year":"2016","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.dld.2023.09.023_bib0006","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/liv.14274","article-title":"Liver fibrosis by FibroScan((R)) independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes","volume":"40","author":"Lombardi","year":"2020","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.dld.2023.09.023_bib0007","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.dld.2023.09.023_bib0008","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2023.09.023_bib0009","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.dld.2023.09.023_bib0010","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.dld.2023.09.023_bib0011","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2023.09.023_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11010022","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: a Meta-Analysis of Randomized Controlled Trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.dld.2023.09.023_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211000243","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data","volume":"12","author":"Arai","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.dld.2023.09.023_bib0014","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5114\/ceh.2020.102173","article-title":"SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review","volume":"6","author":"Dwinata","year":"2020","journal-title":"Clin Exp Hepatol"},{"issue":"9","key":"10.1016\/j.dld.2023.09.023_bib0015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"41","key":"10.1016\/j.dld.2023.09.023_bib0016","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.3748\/wjg.v19.i41.6969","article-title":"PNPLA3 I148M polymorphism and progressive liver disease","volume":"19","author":"Dongiovanni","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.dld.2023.09.023_bib0017","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cgh.2018.11.011","article-title":"FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage","volume":"18","author":"Lombardi","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.dld.2023.09.023_bib0018","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.dld.2023.09.023_bib0019","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years","volume":"59","author":"Wong","year":"2010","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.dld.2023.09.023_bib0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.dld.2023.09.023_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2019.107512","article-title":"Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements","volume":"34","author":"Mikolasevic","year":"2020","journal-title":"J Diabetes Complications"},{"issue":"3","key":"10.1016\/j.dld.2023.09.023_bib0022","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cgh.2018.07.006","article-title":"Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease","volume":"17","author":"Kim","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.dld.2023.09.023_bib0023","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/hep.31142","article-title":"Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: a Prospective Cohort Study","volume":"72","author":"Lee","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.dld.2023.09.023_bib0024","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.dld.2023.09.023_bib0025","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.dld.2023.09.023_bib0026","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/hep4.2069","article-title":"Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus","volume":"6","author":"Arai","year":"2022","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.dld.2023.09.023_bib0027","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","article-title":"Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease","volume":"8","author":"Targher","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2023.09.023_bib0028","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"59","year":"2016","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.dld.2023.09.023_bib0029","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep4.2005","article-title":"Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: a 5-year follow-up study","volume":"6","author":"Akuta","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dld.2023.09.023_bib0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2020.10.064","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials","volume":"232","author":"Salah","year":"2021","journal-title":"Am Heart J"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823009830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823009830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:56:51Z","timestamp":1729101411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865823009830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1590865823009830"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2023.09.023","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2023.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}